CARB-X, a public–private partnership aimed at bolstering the antibiotic pipeline, funded a diverse set of 17 early-stage drug development projects in its first year.
Access options
Subscribe to Journal
Get full journal access for 1 year
$259.00
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Preclinical antibiotic pipeline gets a pick-me-up. Nat Rev Drug Discov 16, 741–742 (2017). https://doi.org/10.1038/nrd.2017.213
Published:
Issue Date:
Further reading
-
Protein‐protein interactions as antibiotic targets: A medicinal chemistry perspective
Medicinal Research Reviews (2020)
-
Discovery of 4,6‐bis(2‐(( E )‐benzylidene)hydrazinyl)pyrimidin‐2‐Amine with Antibiotic Activity
ChemistryOpen (2019)
-
Combating resistance while maintaining innovation: the future of antimicrobial stewardship
Future Microbiology (2019)
-
The Infectious Diseases Society of America’s 10 × ’20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × ’20 a Possibility?
Clinical Infectious Diseases (2019)
-
The Therapeutic Pipeline for Pseudomonas aeruginosa Infections
ACS Infectious Diseases (2018)
